Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. Indication
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application outlook
2.2.2. Indication outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Computer Aided Detection Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Industry challenges
3.4. Computer Aided Detection Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Computer Aided Detection: Application Estimates & Trend Analysis
4.1. Computer Aided Detection Market: Key Takeaways
4.2. Computer Aided Detection Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Tuberculosis
4.3.1. Tuberculosis market estimates and forecast 2018 to 2030 (USD Million)
4.4. Breast Cancer
4.4.1. Breast cancer market estimates and forecast 2018 to 2030 (USD Million)
4.5. Lung Cancer
4.5.1. Lung cancer market estimates and forecast 2018 to 2030 (USD Million)
4.6. Colon/Rectal Cancer
4.6.1. Colon/Rectal cancer market estimates and forecast 2018 to 2030 (USD Million)
4.7. Prostate Cancer
4.7.1. Prostate cancer market estimates and forecast 2018 to 2030 (USD Million)
4.8. Liver Cancer
4.8.1. Liver cancer market estimates and forecast 2018 to 2030 (USD Million)
4.9. Bone Cancer
4.9.1. Bone cancer market estimates and forecast 2018 to 2030 (USD Million)
4.10. Cardiovascular/Neurological/Musculoskeletal Cancer
4.10.1. Cardiovascular/neurological/musculoskeletal indications market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Computer Aided Detection: Indication Estimates & Trend Analysis
5.1. Computer Aided Detection Market: Key Takeaways
5.2. Computer Aided Detection Market: Movement & Market Share Analysis, 2022 & 2030
5.3. X-ray Imaging
5.3.1. X-ray market estimates and forecast 2018 to 2030 (USD Million)
5.4. Magnetic Resonance Imaging
5.4.1. Magnetic resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
5.5. Ultrasound Resonance Imaging
5.5.1. Ultrasound resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
5.6. Nuclear Resonance Imaging
5.6.1. Nuclear resonance imaging market estimates and forecast 2018 to 2030 (USD Million)
5.7. Computed Tomography
5.7.1. Computed tomography market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Computer Aided Detection Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Computer Aided Detection Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. EDDA Technology, Inc
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. FUJIFILM Holdings Corporation
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Hologic, Inc
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Koninklijke Philips N.V
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Siemens
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives NANO-X IMAGING LTD.
7.2.6. NANO-X IMAGING LTD.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. CANON MEDICAL SYSTEMS CORPORATION
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. GENERAL ELECTRIC
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. IBM
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Riverain Technologies
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. iCAD Inc
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Median Technologies
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Hitachi Ltd
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. Shimadzu Analytical (India) Pvt. Ltd
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives
7.2.15. Carestream Health
7.2.15.1. Company overview
7.2.15.2. Financial performance
7.2.15.3. Product benchmarking
7.2.15.4. Strategic initiatives
7.2.16. ESAOTE SPA
7.2.16.1. Company overview
7.2.16.2. Financial performance
7.2.16.3. Product benchmarking
7.2.16.4. Strategic initiatives
7.2.17. Narayana Hrudayalaya Ltd
7.2.17.1. Company overview
7.2.17.2. Financial performance
7.2.17.3. Product benchmarking
7.2.17.4. Strategic initiatives
7.2.18. Karyopharm
7.2.18.1. Company overview
7.2.18.2. Financial performance
7.2.18.3. Product benchmarking
7.2.18.4. Strategic initiatives
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/